Rachel Lawrence
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rachel Lawrence has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Kevin Herbert
Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
9 shared publications - Holly Walton
Department of Behavioural Science and Health, Institute of Epidemiology and Healthcare, University College London, London, UK
8 shared publications - Pei Li Ng
Research Department of Behavioural Science and Health, Institute of Epidemiology and Healthcare University College London London UK
8 shared publications - Holly Elphinstone
Research Department of Behavioural Science and Health, University College London (UCL), London, UK
7 shared publications - Raj Mehta
Public Contributor London UK
7 shared publications - Angus I. G. Ramsay
Department of Behavioural Science and Health, University College London, London, UK
6 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Elsevier in SSRN Electronic Journal
Economic Evaluation of Artificial Intelligence Deployment in Lung Cancer Chest Diagnostic Imaging
Background: Lung cancer imposes a heavy burden on the NHS, where rising imaging demand and workforce shortages delay early diagnosis. Despite early promise, real-world cost-effectiveness evidence for artificial intelligence (AI) deployment remains limited.Methods: We evaluated the cost-effectiveness of AI deployment in chest diagnostic imaging versus standard practice for patients referred with potential lung cancer (LC). A short-term decision-tree model evaluated the cost-utility from an NHS and Personal Social Services perspective.Costs and health outcomes were estimated using data from ten NHS England radiology services and published literature, while chest X-ray sensitivity and specificity estimates were derived from a single NHS trust. Cost-effectiveness was assessed using incremental cost-effectiveness ratios, and incremental net monetary benefit (INMBs).Findings: AI deployment showed no evidence of improved health outcomes versus standard practice (incremental quality-adjusted life years [QALYs], <0.001), but reduced costs by £2.05 per patient. The INMB was positive at thresholds £15,000/QALY (£3.62), £20,000/QALY (£4.14) and £30,000/QALY (£5.19) respectively.Chest X-ray specificity was the main driver of incremental costs and QALYs in sensitivity analyses. AI remained less costly and equally effective in all scenarios assessed including hypothetical autonomous AI reporting of high confidence normal images.Interpretation: This evaluation provides early, real‑world evidence consistent with AI deployment in chest imaging for suspected LC being cost-effective through modest cost savings rather than health gains. However, the uncontrolled pre-post design limits causal inference, and concurrent system changes may have influenced results. Scenario analyses suggest that autonomous reporting and shared licensing could deliver additional efficiencies and cost savings.
- 20 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEconomic Evaluation of Artificial Intelligence Deployment in Lung Cancer Chest Diagnostic Imaging
Background: Lung cancer imposes a heavy burden on the NHS, where rising imaging demand and workforce shortages delay early diagnosis. Despite early promise, real-world cost-effectiveness evidence for artificial intelligence (AI) deployment remains limited.Methods: We evaluated the cost-effectiveness of AI deployment in chest diagnostic imaging versus standard practice for patients referred with potential lung cancer (LC). A short-term decision-tree model evaluated the cost-utility from an NHS and Personal Social Services perspective.Costs and health outcomes were estimated using data from ten NHS England radiology services and published literature, while chest X-ray sensitivity and specificity estimates were derived from a single NHS trust. Cost-effectiveness was assessed using incremental cost-effectiveness ratios, and incremental net monetary benefit (INMBs).Findings: AI deployment showed no evidence of improved health outcomes versus standard practice (incremental quality-adjusted life years [QALYs], <0.001), but reduced costs by £2.05 per patient. The INMB was positive at thresholds £15,000/QALY (£3.62), £20,000/QALY (£4.14) and £30,000/QALY (£5.19) respectively.Chest X-ray specificity was the main driver of incremental costs and QALYs in sensitivity analyses. AI remained less costly and equally effective in all scenarios assessed including hypothetical autonomous AI reporting of high confidence normal images.Interpretation: This evaluation provides early, real‑world evidence consistent with AI deployment in chest imaging for suspected LC being cost-effective through modest cost savings rather than health gains. However, the uncontrolled pre-post design limits causal inference, and concurrent system changes may have influenced results. Scenario analyses suggest that autonomous reporting and shared licensing could deliver additional efficiencies and cost savings.
- Open Access
- 5 October 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e105261
Evaluation of Ambient Voice Technology in the National Health Service in England: Protocol for a Phase 2 Study
Background: Ambient voice technology (AVT) uses conversational AI to record and organize clinical consultations in real time. It is being adopted quickly across the National Health Service (NHS). However, evidence about its effects on productivity, costs, or staff experience across different health care settings is limited. Phase 1 of this research program developed a taxonomy, logic model, and outcome framework for evaluating AVT. Phase 2 will carry out a multisite, mixed methods evaluation of AVT in 4 NHS trusts. These include mental health outpatient services, acute hospital outpatient clinics, and accident and emergency departments. Objective: This study aims to explore the real-world impact of AVT on productivity, costs, and staff experience across NHS adult services. Methods: The study includes three parts: (1) a quantitative quasi-experimental analysis of routine NHS data to estimate the impact of AVT on documentation time, clinician activity, and service outcomes; (2) a comprehensive health economic evaluation comprising cost-consequence analysis, cost-benefit analysis, and budget impact modeling; and (3) interviews with up to 36 staff from 3 services (mental health outpatient, acute hospital outpatient, and accident and emergency) to explore their experience of using AVT, their views on its impact, and what helps and gets in the way of its use. Sites will be chosen to include different care settings, organizational environments, and AVT products. Quantitative and economic analyses will use NHS electronic health records and national datasets to understand changes over time and measure the impact of AVT. Interview data will be analyzed using thematic analysis and rapid assessment procedures to identify key themes. All study findings will be combined to give a clear view of AVT and its impact. Results: Data collection is expected to begin in August 2026 and conclude by January 2027. Publication of results is anticipated in February 2027. Conclusions: This evaluation will provide real-world evidence on the productivity, economic, and experiential impacts of AVT in the NHS. Outputs will include peer-reviewed papers, a slide-deck summary for the funder, and a publicly available health economic decision-support tool to help NHS organizations decide whether they should adopt AVT.
- 5 October 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e105261
Open AccessEvaluation of Ambient Voice Technology in the National Health Service in England: Protocol for a Phase 2 Study
Background: Ambient voice technology (AVT) uses conversational AI to record and organize clinical consultations in real time. It is being adopted quickly across the National Health Service (NHS). However, evidence about its effects on productivity, costs, or staff experience across different health care settings is limited. Phase 1 of this research program developed a taxonomy, logic model, and outcome framework for evaluating AVT. Phase 2 will carry out a multisite, mixed methods evaluation of AVT in 4 NHS trusts. These include mental health outpatient services, acute hospital outpatient clinics, and accident and emergency departments. Objective: This study aims to explore the real-world impact of AVT on productivity, costs, and staff experience across NHS adult services. Methods: The study includes three parts: (1) a quantitative quasi-experimental analysis of routine NHS data to estimate the impact of AVT on documentation time, clinician activity, and service outcomes; (2) a comprehensive health economic evaluation comprising cost-consequence analysis, cost-benefit analysis, and budget impact modeling; and (3) interviews with up to 36 staff from 3 services (mental health outpatient, acute hospital outpatient, and accident and emergency) to explore their experience of using AVT, their views on its impact, and what helps and gets in the way of its use. Sites will be chosen to include different care settings, organizational environments, and AVT products. Quantitative and economic analyses will use NHS electronic health records and national datasets to understand changes over time and measure the impact of AVT. Interview data will be analyzed using thematic analysis and rapid assessment procedures to identify key themes. All study findings will be combined to give a clear view of AVT and its impact. Results: Data collection is expected to begin in August 2026 and conclude by January 2027. Publication of results is anticipated in February 2027. Conclusions: This evaluation will provide real-world evidence on the productivity, economic, and experiential impacts of AVT in the NHS. Outputs will include peer-reviewed papers, a slide-deck summary for the funder, and a publicly available health economic decision-support tool to help NHS organizations decide whether they should adopt AVT.
- Open Access
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
What Is the Impact of Introducing AI for Chest X-Ray Diagnostics on the Processing of Results and Their Follow-Up? A Real-World, Mixed Methods Evaluation
Background: The English NHS has prioritized introducing Artificial Intelligence (AI) for chest radiology diagnostics. However, there is little ‘real-world’ evidence on how AI tools work in clinical practice.Methods: Observational, mixed-methods rapid evaluation of impact of AI on processing and follow up of chest x-ray (CXR) results. We triangulated quantitative data from eight NHS sites’ radiology information systems (n=460,663 scans), and qualitative interview data (n=27, including clinicians, IT staff, project managers, and AI suppliers) from four of these eight sites.Findings: Prioritising CXR images interpreted as abnormal by AI saw faster clinical reporting of suspected cancers than clinically normal or mildly abnormal cases (site-level odds ratios ranged from 1.34 to 6.09, all p≤0.01). Impact on proportions of abnormal x-rays needing follow-up varied: 2/8 sites showed significant increases, while 3/8 showed significant decreases. There was no significant increase in numbers of CT scans conducted within three days of CXR reports. Qualitative analysis supported quantitative findings on impact and identified potential contributing factors, e.g. preexisting activity levels and backlogs, additional investments in diagnostic pathways, and readers’ experience levels.Interpretation: Through worklist prioritisation and clinical decision support, AI may contribute to improved radiology workflows. However, varied impact of AI tools across sites suggests that clinical and organisational context and implementation approaches can influence the extent of impact.
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessWhat Is the Impact of Introducing AI for Chest X-Ray Diagnostics on the Processing of Results and Their Follow-Up? A Real-World, Mixed Methods Evaluation
Background: The English NHS has prioritized introducing Artificial Intelligence (AI) for chest radiology diagnostics. However, there is little ‘real-world’ evidence on how AI tools work in clinical practice.Methods: Observational, mixed-methods rapid evaluation of impact of AI on processing and follow up of chest x-ray (CXR) results. We triangulated quantitative data from eight NHS sites’ radiology information systems (n=460,663 scans), and qualitative interview data (n=27, including clinicians, IT staff, project managers, and AI suppliers) from four of these eight sites.Findings: Prioritising CXR images interpreted as abnormal by AI saw faster clinical reporting of suspected cancers than clinically normal or mildly abnormal cases (site-level odds ratios ranged from 1.34 to 6.09, all p≤0.01). Impact on proportions of abnormal x-rays needing follow-up varied: 2/8 sites showed significant increases, while 3/8 showed significant decreases. There was no significant increase in numbers of CT scans conducted within three days of CXR reports. Qualitative analysis supported quantitative findings on impact and identified potential contributing factors, e.g. preexisting activity levels and backlogs, additional investments in diagnostic pathways, and readers’ experience levels.Interpretation: Through worklist prioritisation and clinical decision support, AI may contribute to improved radiology workflows. However, varied impact of AI tools across sites suggests that clinical and organisational context and implementation approaches can influence the extent of impact.
- Open Access
- 28 July 2026
- Published by BMJ in BMJ Digital Health & AI
- Vol. 2 (1) , e000120
The use of ambient voice technology (AVT) for clinician–patient consultations in healthcare practice: A rapid systematic scoping review
Objective: Using ambient voice technology (AVT) to transcribe and summarise clinician–patient consultations in real time is increasing in healthcare practice, with the aim of reducing clinical documentation burden. However, the evidence base remains underdeveloped. This review synthesised current evidence on the use and impact of AVT for documenting clinician–patient consultations in healthcare. We also examined how impact has been evaluated and measured with the aim of informing future research and assessment in real-world practice. Methods: We conducted a rapid systematic scoping review (PROSPERO: CRD420251155579). Four databases and grey literature sources were searched in September 2025. Of 598 articles screened, 21 met the inclusion criteria. These studies evaluated user experiences with AVT (n = 13), quantified impacts using objective numerical data (n = 19) and perceived impacts based on self-reported experiences (n = 17). Results: Evidence on the real-world impact of AVT remains limited. While some studies report reduced documentation burden and improvements in staff well-being and perceived care quality, these findings largely stem from short-term observational designs and self-reported measures. Evidence relating to wider, system-level impacts such as pathway productivity, patient safety and cost effectiveness is sparse. Approaches to evaluating AVT were heterogeneous and inconsistent, particularly when reporting on system-level impacts beyond the clinician–patient consultation. Different factors (e.g., workflow integration, output quality), the consultation context and clinical setting influenced experiences of using AVT. Conclusions: Current evidence does not yet support widespread adoption of AVT in clinical practice. Although early findings suggest potentially important benefits, available studies are heterogeneous, predominantly short-term and methodologically limited. It remains unclear whether the improvements reported to date translate into sustained gains in clinical capacity, care quality or system efficiency. Longer-term evaluations using standardised outcome measures complemented by qualitative methods, are needed to determine the impact and value of AVT in healthcare. PROSPERO registration number: CRD420251155579.
- 28 July 2026
- Published by BMJ in BMJ Digital Health & AI
- Vol. 2 (1) , e000120
Open AccessThe use of ambient voice technology (AVT) for clinician–patient consultations in healthcare practice: A rapid systematic scoping review
Objective: Using ambient voice technology (AVT) to transcribe and summarise clinician–patient consultations in real time is increasing in healthcare practice, with the aim of reducing clinical documentation burden. However, the evidence base remains underdeveloped. This review synthesised current evidence on the use and impact of AVT for documenting clinician–patient consultations in healthcare. We also examined how impact has been evaluated and measured with the aim of informing future research and assessment in real-world practice. Methods: We conducted a rapid systematic scoping review (PROSPERO: CRD420251155579). Four databases and grey literature sources were searched in September 2025. Of 598 articles screened, 21 met the inclusion criteria. These studies evaluated user experiences with AVT (n = 13), quantified impacts using objective numerical data (n = 19) and perceived impacts based on self-reported experiences (n = 17). Results: Evidence on the real-world impact of AVT remains limited. While some studies report reduced documentation burden and improvements in staff well-being and perceived care quality, these findings largely stem from short-term observational designs and self-reported measures. Evidence relating to wider, system-level impacts such as pathway productivity, patient safety and cost effectiveness is sparse. Approaches to evaluating AVT were heterogeneous and inconsistent, particularly when reporting on system-level impacts beyond the clinician–patient consultation. Different factors (e.g., workflow integration, output quality), the consultation context and clinical setting influenced experiences of using AVT. Conclusions: Current evidence does not yet support widespread adoption of AVT in clinical practice. Although early findings suggest potentially important benefits, available studies are heterogeneous, predominantly short-term and methodologically limited. It remains unclear whether the improvements reported to date translate into sustained gains in clinical capacity, care quality or system efficiency. Longer-term evaluations using standardised outcome measures complemented by qualitative methods, are needed to determine the impact and value of AVT in healthcare. PROSPERO registration number: CRD420251155579.
- Open Access
- 3 July 2026
- Published by Wiley in Health Expectations
- Vol. 29 (4) , e70750
“That's All We Wanted, to Be Heard, Listened to, Just to Be Validated and Believed”: Family Experiences of Advocacy Support in Maternity and Neonatal Services
Background: Systemic failures in maternity and neonatal care have resulted in adverse outcomes for families. The 2020 Ockenden review (interim findings) recommended creating an Independent Senior Advocate Role as an Immediate and Essential Action. During 2024–March 2026, the Maternity and Neonatal Independent Senior Advocate (MNISA) service was piloted in 16 Integrated Care Boards (ICBs) and aimed to (1) enable families to feel listened to and heard, with their concerns acted upon, and (2) influence system change. MNISAs supported families following the death or serious injury of a mother or baby during NHS care. Objective: To explore the experiences of families who did, and did not, receive MNISA support and the perceived impact of MNISAs. Design: A rapid qualitative study with families who did, and did not, receive MNISA support in 11 ICBs. Interviews were conducted, or written responses to interview questions were collected via an electronic survey tool. All responses were analysed using rapid assessment procedure sheets and inductive thematic analysis. Results: We interviewed 34 families ( n = 31 received support and n = 3 did not, but were eligible). Findings indicate that MNISAs met service aims by listening to and validating families, enabling their voices to be heard, supporting them to navigate investigative processes and understand their care, facilitating family‐led change. MNISA support was continuous, which helped to alleviate the emotional overwhelm that families experienced. Important barriers to access and engagement were identified. Families who did not receive the service indicated that they would have valued independent advocacy support. All families felt that the service should continue. Conclusions: Independent advocacy in maternity care creates opportunities for families to be heard and listened to, supporting family‐led change. Further research is essential to understand the ongoing and sustained impact of independent advocacy on family experiences, how the positioning of these services can facilitate equitable access and their role in preventing avoidable harm.
- 3 July 2026
- Published by Wiley in Health Expectations
- Vol. 29 (4) , e70750
Open Access“That's All We Wanted, to Be Heard, Listened to, Just to Be Validated and Believed”: Family Experiences of Advocacy Support in Maternity and Neonatal Services
Background: Systemic failures in maternity and neonatal care have resulted in adverse outcomes for families. The 2020 Ockenden review (interim findings) recommended creating an Independent Senior Advocate Role as an Immediate and Essential Action. During 2024–March 2026, the Maternity and Neonatal Independent Senior Advocate (MNISA) service was piloted in 16 Integrated Care Boards (ICBs) and aimed to (1) enable families to feel listened to and heard, with their concerns acted upon, and (2) influence system change. MNISAs supported families following the death or serious injury of a mother or baby during NHS care. Objective: To explore the experiences of families who did, and did not, receive MNISA support and the perceived impact of MNISAs. Design: A rapid qualitative study with families who did, and did not, receive MNISA support in 11 ICBs. Interviews were conducted, or written responses to interview questions were collected via an electronic survey tool. All responses were analysed using rapid assessment procedure sheets and inductive thematic analysis. Results: We interviewed 34 families ( n = 31 received support and n = 3 did not, but were eligible). Findings indicate that MNISAs met service aims by listening to and validating families, enabling their voices to be heard, supporting them to navigate investigative processes and understand their care, facilitating family‐led change. MNISA support was continuous, which helped to alleviate the emotional overwhelm that families experienced. Important barriers to access and engagement were identified. Families who did not receive the service indicated that they would have valued independent advocacy support. All families felt that the service should continue. Conclusions: Independent advocacy in maternity care creates opportunities for families to be heard and listened to, supporting family‐led change. Further research is essential to understand the ongoing and sustained impact of independent advocacy on family experiences, how the positioning of these services can facilitate equitable access and their role in preventing avoidable harm.
- Open Access
- 23 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Evaluation of Ambient Voice Technology in the NHS In England: Phase 2 Study Protocol (Preprint)
BACKGROUND Ambient Voice Technology (AVT) uses conversational artificial intelligence to record and organise clinical consultations in real time. It is being adopted quickly across the NHS. However, evidence about its effects on productivity, costs, or staff experience across different healthcare settings is limited. Phase 1 of this research programme developed a taxonomy, logic model, and outcome framework for evaluating AVT. Phase 2 will carry out a multi-site, mixed-methods evaluation of AVT in four NHS trusts. These include mental health outpatient services, acute hospital outpatient clinics, and accident and emergency departments. OBJECTIVE This study aims to explore the real-world impact of AVT on productivity, costs, and staff experience across NHS adult services. METHODS The study includes three parts. (i) A quantitative quasi-experimental analysis of routine NHS data to estimate the impact of AVT on documentation time, clinician activity, and service outcomes. (ii) A comprehensive health economic evaluation comprising cost-consequence analysis, cost-benefit analysis, and budget impact modelling. (iii) Interviews with up to 36 staff from three services (mental health outpatient, acute hospital outpatient, and accident and emergency) to explore their experience of using AVT, their views on its impact, and what helps and gets in the way of its use. Sites will be chosen to include different care settings, organisational environments, and AVT products. Quantitative and economic analyses will use NHS electronic health records and national datasets to understand changes over time and measure the impact of AVT. Interview data will be analysed using thematic analysis and rapid assessment procedures to identify key themes. All study findings will be combined to give a clear view of AVT and its impact. RESULTS Data collection is expected to begin in August 2026 and conclude by January 2027. Publication of results is anticipated in February 2027. CONCLUSIONS This evaluation will provide real-world evidence on the productivity, economic, and experiential impacts of AVT in the NHS. Outputs will include peer-reviewed papers, a slide-deck summary for the funder, and a publicly available health economic decision-support tool to help NHS organisations decide if they should adopt AVT.
- 23 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEvaluation of Ambient Voice Technology in the NHS In England: Phase 2 Study Protocol (Preprint)
BACKGROUND Ambient Voice Technology (AVT) uses conversational artificial intelligence to record and organise clinical consultations in real time. It is being adopted quickly across the NHS. However, evidence about its effects on productivity, costs, or staff experience across different healthcare settings is limited. Phase 1 of this research programme developed a taxonomy, logic model, and outcome framework for evaluating AVT. Phase 2 will carry out a multi-site, mixed-methods evaluation of AVT in four NHS trusts. These include mental health outpatient services, acute hospital outpatient clinics, and accident and emergency departments. OBJECTIVE This study aims to explore the real-world impact of AVT on productivity, costs, and staff experience across NHS adult services. METHODS The study includes three parts. (i) A quantitative quasi-experimental analysis of routine NHS data to estimate the impact of AVT on documentation time, clinician activity, and service outcomes. (ii) A comprehensive health economic evaluation comprising cost-consequence analysis, cost-benefit analysis, and budget impact modelling. (iii) Interviews with up to 36 staff from three services (mental health outpatient, acute hospital outpatient, and accident and emergency) to explore their experience of using AVT, their views on its impact, and what helps and gets in the way of its use. Sites will be chosen to include different care settings, organisational environments, and AVT products. Quantitative and economic analyses will use NHS electronic health records and national datasets to understand changes over time and measure the impact of AVT. Interview data will be analysed using thematic analysis and rapid assessment procedures to identify key themes. All study findings will be combined to give a clear view of AVT and its impact. RESULTS Data collection is expected to begin in August 2026 and conclude by January 2027. Publication of results is anticipated in February 2027. CONCLUSIONS This evaluation will provide real-world evidence on the productivity, economic, and experiential impacts of AVT in the NHS. Outputs will include peer-reviewed papers, a slide-deck summary for the funder, and a publicly available health economic decision-support tool to help NHS organisations decide if they should adopt AVT.
- Open Access
- 1 March 2026
- Published by National Institute for Health and Care Research in Health and Social Care Delivery Research
- p. 1-42
Implementing artificial intelligence in chest diagnostics for lung disease: A mixed-methods evaluation
Background: Artificial intelligence tools simulate aspects of human intelligence. Policy and research highlight artificial intelligence’s potential to support delivery of radiology pathways. In 2023, National Health Service (NHS) England invested £21M to deploy artificial intelligence diagnostic tools for chest X-ray and chest computed tomography in 66 NHS Trusts. Little is known about how artificial intelligence tools are implemented in practice, staff experience of these tools, and their effectiveness and cost. Objectives: Evaluate evidence on artificial intelligence tools within radiology internationally. Evaluate implementation of artificial intelligence for chest diagnostics in England. Investigate how effectiveness and cost-effectiveness of artificial intelligence for chest diagnostics can be measured. Methods: Ten-month mixed-methods study (rapid scoping review and empirical study comprising staff interviews, observations and documentary analysis). Findings were analysed using rapid assessment procedures, drawing on qualitative, quantitative and health economic approaches. Our evaluation was also designed to inform phase 2 of our study. Findings: The review included 114 articles on artificial intelligence use in radiology, internationally. Empirical work included 51 staff interviews, 57 observations and 166 documents from 10/11 of the networks and 6/66 trusts implementing artificial intelligence tools. Our review found evidence gaps, including real-world implementation of artificial intelligence tools; patient and carer experiences; impact on inequalities, sustainability and wider systems; and cost-effectiveness. Artificial intelligence for chest diagnostics was implemented in various ways, with different aims, pathways and approaches. Implementation takes time due to multiple activities related to planning, procurement, preparation for deployment, monitoring and evaluation. These tasks – technical and social – required time and resource, including a wide range of stakeholders and expertise. As of November 2024, 24/66 trusts had implemented artificial intelligence tools in practice. Implementation barriers included time, resources, challenges navigating processes and adapting these to local contexts. Facilitators included stakeholder engagement and support. Network and trust ability to evaluate service impact was influenced by factors such as data availability, data linkage, resources and capacity. Factors varied across implementation stages. Our findings indicated multiple data sources that may support measurement of effectiveness and cost-effectiveness within the English National Health Service. However, limitations to data availability need to be addressed. Limitations: Our rapid timeline meant we could not interview patients, carers, and several staff groups at trust and national levels. Delayed deployment meant we could not study implementation in practice or staff experiences. Future work: Should address real-world implementation, adaptation, and sustainability of artificial intelligence tools; impact of artificial intelligence on care, outcomes, and cost-effectiveness; and staff, patient, and carer experiences of artificial intelligence in practice. We will study these issues in phase 2 of our evaluation. Conclusions: Artificial intelligence tools may support effective, efficient chest diagnostics services. However, several factors should be considered when implementing and monitoring artificial intelligence tools. Implementation and monitoring may be improved through allowing sufficient time for procurement and preparation for deployment or extending capacity to speed completion of these tasks, early and ongoing stakeholder engagement, sufficient resourcing, dedicated expertise and clinical champions, simplifying governance processes, and improving data capacity. Parallels with learning from implementing other innovations suggests that artificial intelligence tools may not offer straightforward solutions anticipated by services and policy-makers. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme as award number NIHR167339.
- 1 March 2026
- Published by National Institute for Health and Care Research in Health and Social Care Delivery Research
- p. 1-42
Open AccessImplementing artificial intelligence in chest diagnostics for lung disease: A mixed-methods evaluation
Background: Artificial intelligence tools simulate aspects of human intelligence. Policy and research highlight artificial intelligence’s potential to support delivery of radiology pathways. In 2023, National Health Service (NHS) England invested £21M to deploy artificial intelligence diagnostic tools for chest X-ray and chest computed tomography in 66 NHS Trusts. Little is known about how artificial intelligence tools are implemented in practice, staff experience of these tools, and their effectiveness and cost. Objectives: Evaluate evidence on artificial intelligence tools within radiology internationally. Evaluate implementation of artificial intelligence for chest diagnostics in England. Investigate how effectiveness and cost-effectiveness of artificial intelligence for chest diagnostics can be measured. Methods: Ten-month mixed-methods study (rapid scoping review and empirical study comprising staff interviews, observations and documentary analysis). Findings were analysed using rapid assessment procedures, drawing on qualitative, quantitative and health economic approaches. Our evaluation was also designed to inform phase 2 of our study. Findings: The review included 114 articles on artificial intelligence use in radiology, internationally. Empirical work included 51 staff interviews, 57 observations and 166 documents from 10/11 of the networks and 6/66 trusts implementing artificial intelligence tools. Our review found evidence gaps, including real-world implementation of artificial intelligence tools; patient and carer experiences; impact on inequalities, sustainability and wider systems; and cost-effectiveness. Artificial intelligence for chest diagnostics was implemented in various ways, with different aims, pathways and approaches. Implementation takes time due to multiple activities related to planning, procurement, preparation for deployment, monitoring and evaluation. These tasks – technical and social – required time and resource, including a wide range of stakeholders and expertise. As of November 2024, 24/66 trusts had implemented artificial intelligence tools in practice. Implementation barriers included time, resources, challenges navigating processes and adapting these to local contexts. Facilitators included stakeholder engagement and support. Network and trust ability to evaluate service impact was influenced by factors such as data availability, data linkage, resources and capacity. Factors varied across implementation stages. Our findings indicated multiple data sources that may support measurement of effectiveness and cost-effectiveness within the English National Health Service. However, limitations to data availability need to be addressed. Limitations: Our rapid timeline meant we could not interview patients, carers, and several staff groups at trust and national levels. Delayed deployment meant we could not study implementation in practice or staff experiences. Future work: Should address real-world implementation, adaptation, and sustainability of artificial intelligence tools; impact of artificial intelligence on care, outcomes, and cost-effectiveness; and staff, patient, and carer experiences of artificial intelligence in practice. We will study these issues in phase 2 of our evaluation. Conclusions: Artificial intelligence tools may support effective, efficient chest diagnostics services. However, several factors should be considered when implementing and monitoring artificial intelligence tools. Implementation and monitoring may be improved through allowing sufficient time for procurement and preparation for deployment or extending capacity to speed completion of these tasks, early and ongoing stakeholder engagement, sufficient resourcing, dedicated expertise and clinical champions, simplifying governance processes, and improving data capacity. Parallels with learning from implementing other innovations suggests that artificial intelligence tools may not offer straightforward solutions anticipated by services and policy-makers. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme as award number NIHR167339.
- Open Access
- 31 October 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e81421
Implementation, Experiences, Impact, and Costs of Artificial Intelligence in Chest Diagnostics: Protocol for a Mixed Methods Evaluation
Background: The ability to perform complex tasks has seen artificial intelligence (AI) used to support radiology in clinical settings, including lung cancer detection and diagnosis. Evidence suggests that AI can contribute to accurate diagnosis, reduce errors, and improve efficiency. The National Health Service England (NHSE)–funded Artificial Intelligence Diagnostic Fund (AIDF) is currently supporting 12 National Health Service (NHS) networks to implement AI for chest diagnostic imaging. There is, however, limited evidence on real-world AI implementation and use, including staff, patient, and caregiver experience, and costs and cost-effectiveness. A National Institute for Health and Care Research Rapid Service Evaluation Team Phase 1 evaluation provided insights into the early implementation of these tools and developed a framework for monitoring and evaluation of AI tools for chest diagnostic imaging in practice. Objective: This mixed methods evaluation of AI tools for chest diagnostic imaging aims to address previous research gaps by exploring the implementation of AI tools for chest diagnostic imaging, the impact and costs of implementing these service models, and the experiences of patients, caregivers, and staff. Methods: This study will be a mixed method evaluation of implementation, experiences, impact, and costs of AI for chest diagnostic imaging in NHS services in England, with the evaluation informed by the Major System Change Framework. Trust-level case studies (3 in-depth and up to 9 light-touch) will be performed, including staff member, patient, and caregiver; NHSE AIDF team interviews; meeting observations; and analysis of key relevant documentation. Qualitative data will be analyzed using Rapid Assessment Procedures and inductive thematic analysis, supplemented by in-depth deductive thematic analysis. Data from case study sites and other relevant sources will be used to assess outcomes at the other sites and for comparators. A pragmatic economic model of the chest diagnostic imaging pathway will be developed to estimate key costs and resource use associated with AI tool deployment. Together with input from national stakeholders and staff workshops, the study findings will then be finalized for reporting. Results: As of September 2025, trust-level research and development approvals with participating sites are complete, and data collection has commenced. Results are expected to be reported by the end of February 2026. Conclusions: The study will provide new insights into the facilitators and barriers to the adoption of AI technology in health care and the perceptions of both the general public and health care staff on its use. It will also inform best practices in approaches for service performance evaluation, for the implementation of AI into existing care pathways, and for the development of models to best support evidence-based decision-making. It will thus establish a framework upon which the greatest benefits of the use of AI in health care can be realized. International Registered Report Identifier (IRRID): DERR1-10.2196/81421
- 31 October 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e81421
Open AccessImplementation, Experiences, Impact, and Costs of Artificial Intelligence in Chest Diagnostics: Protocol for a Mixed Methods Evaluation
Background: The ability to perform complex tasks has seen artificial intelligence (AI) used to support radiology in clinical settings, including lung cancer detection and diagnosis. Evidence suggests that AI can contribute to accurate diagnosis, reduce errors, and improve efficiency. The National Health Service England (NHSE)–funded Artificial Intelligence Diagnostic Fund (AIDF) is currently supporting 12 National Health Service (NHS) networks to implement AI for chest diagnostic imaging. There is, however, limited evidence on real-world AI implementation and use, including staff, patient, and caregiver experience, and costs and cost-effectiveness. A National Institute for Health and Care Research Rapid Service Evaluation Team Phase 1 evaluation provided insights into the early implementation of these tools and developed a framework for monitoring and evaluation of AI tools for chest diagnostic imaging in practice. Objective: This mixed methods evaluation of AI tools for chest diagnostic imaging aims to address previous research gaps by exploring the implementation of AI tools for chest diagnostic imaging, the impact and costs of implementing these service models, and the experiences of patients, caregivers, and staff. Methods: This study will be a mixed method evaluation of implementation, experiences, impact, and costs of AI for chest diagnostic imaging in NHS services in England, with the evaluation informed by the Major System Change Framework. Trust-level case studies (3 in-depth and up to 9 light-touch) will be performed, including staff member, patient, and caregiver; NHSE AIDF team interviews; meeting observations; and analysis of key relevant documentation. Qualitative data will be analyzed using Rapid Assessment Procedures and inductive thematic analysis, supplemented by in-depth deductive thematic analysis. Data from case study sites and other relevant sources will be used to assess outcomes at the other sites and for comparators. A pragmatic economic model of the chest diagnostic imaging pathway will be developed to estimate key costs and resource use associated with AI tool deployment. Together with input from national stakeholders and staff workshops, the study findings will then be finalized for reporting. Results: As of September 2025, trust-level research and development approvals with participating sites are complete, and data collection has commenced. Results are expected to be reported by the end of February 2026. Conclusions: The study will provide new insights into the facilitators and barriers to the adoption of AI technology in health care and the perceptions of both the general public and health care staff on its use. It will also inform best practices in approaches for service performance evaluation, for the implementation of AI into existing care pathways, and for the development of models to best support evidence-based decision-making. It will thus establish a framework upon which the greatest benefits of the use of AI in health care can be realized. International Registered Report Identifier (IRRID): DERR1-10.2196/81421
- Open Access
- 11 September 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 89, 103481
Procurement and early deployment of artificial intelligence tools for chest diagnostics in NHS services in England: a rapid, mixed method evaluation
- 11 September 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 89, 103481
Open AccessProcurement and early deployment of artificial intelligence tools for chest diagnostics in NHS services in England: a rapid, mixed method evaluation
- Open Access
- 9 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331562
The experience of cerebral palsy stigma amongst adults living in the UK and Ireland: A qualitative co-designed project
Background: There is evidence that cerebral palsy (CP) could be linked to stigma and discrimination, however current evidence is limited to small qualitative studies. The goal of this co-designed survey was to elicit information on experiences of stigma and discrimination amongst a larger sample of adults in the UK and Ireland. Methods: Quantitative questions about sources of stigma and qualitative questions designed to elicit information on experiences of stigma were shared via an online survey. Results: Eighty-six people completed the qualitative survey, and 5 themes were generated that captured experiences of stigma and discrimination. Theme 1 (rigid stereotypes) captured the lack of awareness about the heterogeneity of CP. Theme 2 (impact on participation) highlighted the difficulties that participants had with participation, particularly in terms of accessibility and sexual relationships. Theme 3 (interpersonal difficulties) included the difficulties people with CP had in interactions with the public such as feel visible in some situations, invisible in others and being infantilised. Theme 4 (systematic discrimination) highlighted discrimination in the workplace, healthcare and broader environment. Theme 5 (negative emotional impact) captured the negative emotional impact that experiences of stigma and discrimination had. Quantitative responses from 48 participants indicated that stigma was a common experience (experienced by 87.5% of respondents), and the most common sources of stigma were the public, classmates and coworkers. Conclusions: Results indicate that CP is linked to experiences of stigma and discrimination which arise from a lack of understanding of the heterogeneity of CP, a public lack of awareness of how to communicate with people with disabilities, inaccessible environments and negative societal attitudes towards visible impairments. Suggested ways to tackle these issues include improving understanding of CP and removing barriers to accessibility.
- 9 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331562
Open AccessThe experience of cerebral palsy stigma amongst adults living in the UK and Ireland: A qualitative co-designed project
Background: There is evidence that cerebral palsy (CP) could be linked to stigma and discrimination, however current evidence is limited to small qualitative studies. The goal of this co-designed survey was to elicit information on experiences of stigma and discrimination amongst a larger sample of adults in the UK and Ireland. Methods: Quantitative questions about sources of stigma and qualitative questions designed to elicit information on experiences of stigma were shared via an online survey. Results: Eighty-six people completed the qualitative survey, and 5 themes were generated that captured experiences of stigma and discrimination. Theme 1 (rigid stereotypes) captured the lack of awareness about the heterogeneity of CP. Theme 2 (impact on participation) highlighted the difficulties that participants had with participation, particularly in terms of accessibility and sexual relationships. Theme 3 (interpersonal difficulties) included the difficulties people with CP had in interactions with the public such as feel visible in some situations, invisible in others and being infantilised. Theme 4 (systematic discrimination) highlighted discrimination in the workplace, healthcare and broader environment. Theme 5 (negative emotional impact) captured the negative emotional impact that experiences of stigma and discrimination had. Quantitative responses from 48 participants indicated that stigma was a common experience (experienced by 87.5% of respondents), and the most common sources of stigma were the public, classmates and coworkers. Conclusions: Results indicate that CP is linked to experiences of stigma and discrimination which arise from a lack of understanding of the heterogeneity of CP, a public lack of awareness of how to communicate with people with disabilities, inaccessible environments and negative societal attitudes towards visible impairments. Suggested ways to tackle these issues include improving understanding of CP and removing barriers to accessibility.